MedTrace Logo

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2025-08-03

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

Conditions

Interventions

DRUG

Ramucirumab

Administered IV

DRUG

Merestinib

Administered orally

DRUG

Cisplatin

Administered IV

DRUG

Gemcitabine

Administered IV

DRUG

Placebo Oral

Administered orally

DRUG

Placebo IV

Administered IV

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-19
Primary Completion
2018-02-16
Completion
2026-12-31

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • France
  • Germany
  • Hungary
  • Mexico
  • Russia
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02711553 on ClinicalTrials.gov